State Street’s Hepion Pharmaceuticals HEPA Stock Holding History

State Street’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-314	Closed	-$7.37K	–	4298
2024 Q4	$7.37K	Hold	314	–	–	﹤0.01%	4288
2024 Q3	$10.5K	Hold	314	–	–	﹤0.01%	4260
2024 Q2	$16.9K	Hold	314	–	–	﹤0.01%	4289
2024 Q1	$39K	Hold	314	–	–	﹤0.01%	4201
2023 Q4	$51.3K	Hold	314	–	–	﹤0.01%	4194
2023 Q3	$78.2K	Hold	314	–	–	﹤0.01%	4171
2023 Q2	$165K	Hold	314	–	–	﹤0.01%	4060
2023 Q1	$243K	Hold	314	–	–	﹤0.01%	4001
2022 Q4	$94.1K	Hold	314	–	–	﹤0.01%	4387
2022 Q3	$158K	Hold	314	–	–	﹤0.01%	4236
2022 Q2	$179K	Sell	314 -35	-10%	-$29.1K	﹤0.01%	4261
2022 Q1	$450K	Buy	349 +26	+8%	+$28.7K	﹤0.01%	4094
2021 Q4	$368K	Hold	323	–	–	﹤0.01%	4117
2021 Q3	$494K	Hold	323	–	–	﹤0.01%	3983
2021 Q2	$639K	Buy	+323	New	+$591K	﹤0.01%	3774

Other funds holding HEPA

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's HEPA Position: Q1 2025 in Review

State Street sold out of Hepion Pharmaceuticals (HEPA) in Q1 2025, closing a stake of 314 shares — an estimated $7.37K sold.

State Street first reported a position in HEPA in Q2 2021 and held it in 15 quarters. The position peaked at $639K in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q1 2025.

State Street reported no remaining Hepion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
State Street sold 314 Hepion Pharmaceuticals shares in Q1 2025, an estimated $7.37K.
State Street first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 15 quarters.
State Street's Hepion Pharmaceuticals position peaked at $639K in Q2 2021.
16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2025.

Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.